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Cardiac remodeling is generally accepted as a determinant of the clinical course of heart
failure (HF). Defined as genome expression resulting in molecular, cellular and interstitial
changes and manifested clinically as changes in size, shape and function of the heart resulting
from cardiac load or injury, cardiac remodeling is influenced by hemodynamic load,
neurohormonal activation and other factors still under investigation.
Although patients with major remodeling demonstrate progressive worsening of cardiac
function, slowing or reversing remodeling has only recently become a goal of HF therapy.
Mechanisms other than remodeling can also influence the course of heart disease, and disease
progression may occur in other ways in the absence of cardiac remodeling.
Left ventricular end-diastolic and end-systolic volume and ejection fraction data provide
support for the beneficial effects of therapeutic agents such as angiotensin-converting enzyme
(ACE) inhibitors and beta-adrenergic blocking agents on the remodeling process. These
agents also provide benefits in terms of morbidity and mortality. Although measurement of
ejection fraction can reliably guide initiation of treatment in HF, opinions differ regarding the
value of ejection fraction data in guiding ongoing therapy. The role of echocardiography or
radionuclide imaging in the management and monitoring of HF is as yet unclear.
To fully appreciate the potential benefits of HF therapies, clinicians should understand the
relationship between remodeling and HF progression. Their patients may then, in turn,
acquire an improved understanding of their disease and the treatments they are given. (J Am
Coll Cardiol 2000;35:569–82) © 2000 by the American College of Cardiology
Heart failure (HF) can no longer be considered a simple
contractile disorder or a disease of the heart alone. Clinical
manifestations are, in fact, the result of changes to the
heart’s cellular and molecular components and to mediators
that drive homeostatic control. There is general acceptance
that as heart disease progresses into HF, heart size increases,
cardiac function deteriorates and symptoms of HF become
evident. Although different terms have been used to de-
scribe it, cardiac remodeling encompasses many changes
associated with progressive HF.
Therapeutic interventions aimed solely at correcting a
low cardiac output or reduced blood flow—those offering
symptomatic relief or improved cardiac emptying—do
not necessarily slow HF progression or reduce mortality
(1–3). Antineuroendocrine treatment with angiotensin-
converting enzyme (ACE) inhibition, beta-adrenergic
blocking agents and antialdosterone therapy are associ-
ated with significant reductions in morbidity and mor-
tality in HF (4 –12). Both ACE inhibition and beta-
blockade are also known to slow, and in some cases even
reverse, certain parameters of cardiac remodeling in HF
patients (8,13–16). Cardiac remodeling is now recog-
nized as an important aspect of cardiovascular disease
progression and is, therefore, emerging as a therapeutic
target in HF of all etiologies.
In April 1998, we held a meeting in Atlanta, Georgia,
with the specific aim of examining the interrelationship
between HF progression and cardiac remodeling. The
International Forum on Cardiac Remodeling drew together
interested physicians to discuss the basic mechanisms of
cardiac remodeling, the potential link between cardiac
remodeling and HF progression and the influence of ther-
apeutic interventions on the remodeling process. This paper
provides the consensus views on key concepts and defini-
tions, supporting data and issues about cardiac remodeling
which emerged from that meeting.
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CONCEPTS OF CARDIAC REMODELING
CONSENSUS STATEMENT ONE
Cardiac remodeling may be defined as genome expression,
molecular, cellular and interstitial changes that are mani-
fested clinically as changes in size, shape and function of the
heart after cardiac injury. The process of cardiac remodeling
is influenced by hemodynamic load, neurohormonal activa-
tion and other factors still under investigation. The myocyte
is the major cardiac cell involved in the remodeling process.
Other components involved include the interstitium, fibro-
blasts, collagen and coronary vasculature; relevant processes
also include ischemia, cell necrosis and apoptosis.
When does remodeling occur? Cardiac remodeling can
be described as a physiologic and pathologic condition
that may occur after myocardial infarction (MI), pressure
overload (aortic stenosis, hypertension), inflammatory
heart muscle disease (myocarditis), idiopathic dilated
cardiomyopathy or volume overload (valvular regurgita-
tion). Although the etiologies of these diseases are
different, they share several pathways in terms of molec-
ular, biochemical and mechanical events. Physiologic re-
modeling—compensatory changes in the proportions and
function of the heart—is seen in athletes, but will not be
discussed further in this paper.
In postinfarct models, the process of left ventricular (LV)
remodeling begins rapidly—usually within the first few
hours after an infarct—and continues to progress (17–19).
The time course of events is influenced, however, by the
severity of the underlying disease, secondary events (such as
recurrent MI), other factors (such as ischemia or neuroen-
docrine activation), genotype and treatment (20–23). Ani-
mal studies also show that infarct expansion, regional
dilation and thinning of the infarct zone can occur within
one day of an MI (21). Severe impairment of global
ventricular function—a functional and clinical phenomenon
that can be differentiated clearly from LV remodeling—can
be observed within two days of an insult (24). The changes
that occur after an insult are summarized in Table 1
(20,21,24–28).
Although an exact picture of all the pathways and cells
involved in LV remodeling is still unclear, the following
scenario has been proposed at a molecular level. As myo-
cytes stretch, local norepinephrine activity and angiotensin
and endothelin release are increased; many other factors that
are thought to be stimulated are currently being studied.
These changes, in turn, stimulate expression of altered
proteins and myocyte hypertrophy. The end result of this
sequence of events is further deterioration in cardiac per-
formance and increased neurohormonal activation. In addi-
tion, increased activation of aldosterone and cytokines may
also stimulate collagen synthesis, thus leading to fibrosis and
remodeling of the extracellular matrix.
Functional changes associated with remodeling. The
initial remodeling phase leading to reparation of the ne-
crotic area and to scar formation may, to some extent, be
considered beneficial. This cellular rearrangement of the
ventricular wall is associated with maintained or improved
cardiac output but with significantly increased LV volumes.
The magnitude of remodeling changes observed relates
roughly to infarct size. After one month, large infarcts
provoke greater dilation and greater increases in systolic and
diastolic stress than small infarcts (24). In progressive
postinfarction dilation, the end-systolic volume index in-
creases progressively and ejection fraction declines. These
are important predictors of mortality (26,29).
Gross changes to the heart. As the heart remodels, its
geometry changes; it becomes less elliptical and more
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
AIRE 5 Acute Infarction Ramipril Evaluation
Study
ANP 5 atrial natriuretic peptide
ANZ 5 Australia/New Zealand Collaborative
Group
CIBIS II 5 Cardiac Insufficiency Bisoprolol Study
ECG 5 electrocardiogram
HF 5 heart failure
LV 5 left ventricular
MDC 5 Metropol Dilated Cardiomyopathy trial
MERIT-HF 5 Metoprolol CR/XL Randomized
Intervention Trial in Heart Failure
MI 5 myocardial infarction
MRI 5 magnetic resonance imaging
NO 5 nitric oxide
RAS 5 renin angiotensin system
SAVE 5 Survival and Ventricular Enlargement
Study
SNS 5 sympathetic nervous system
SOLVD 5 Studies of Left Ventricular
Dysfunction
TBARS 5 thiobarbituric acid reactive substances
TNF 5 tumor necrosis factor
TRACE 5 Trandolapril Cardiac Evaluation
Study
V-HeFT I and
V-HeFT II 5 Vasodilator Heart Failure Trials
Table 1. Processes Occurring in Ventricular Remodeling
Cardiomyocyte lengthening (21,24)
Ventricular wall thins (21,24,25)
Infarct expansion rather than extension occurs (20,21)
Inflammation and reabsorption of necrotic tissue (21)
Scar formation
Continued expansion of infarct zone (20)
Dilation and reshaping of the left ventricle (21,25–27)
Myocyte hypertrophy (21,24,25,27)
Ongoing myocyte loss
Excessive accumulation of collagen in the cardiac interstitium (28)
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spherical (Fig. 1) (30,31). There are also changes in ven-
tricular mass, composition and volume, all of which may
adversely affect cardiac function (22,24–26,29,32,33) (for
reviews see 28,34).
Cellular and molecular changes in remodeling. Remod-
eling encompasses cellular changes including myocyte hy-
pertrophy, necrosis (35), apoptosis (36–38), fibrosis (39),
increased fibrillar collagen (40) and fibroblast proliferation
(41). Circulating or locally generated angiotensin II is also
thought to play a role in altering gene expression, via
activation of second messenger systems (42–44). Table 2
shows the pathophysiologic changes in response to an
ischemic insult on the myocardium (38,45–47).
INFLUENCES ON CARDIAC REMODELING
Changes in hemodynamic load. Studies of global LV
chamber volumes and muscle mass show that early LV
dilation in patients with anterior wall MI may continue
progressively and unabated; global compensatory (reactive)
ventricular hypertrophy appears to be a delayed and limited
adaptation during the first year (22). As a result of progres-
sive ventricular dilation and insufficient development of
reactive ventricular hypertrophy, global LV wall tension and
stresses increase considerably during this period (reviewed
by Rumberger [48]).
The importance of remodeling as a pathogenic mecha-
nism is unclear, and the factors leading to remodeling may
be the major determinants of HF prognosis rather than
ventricular dilation itself. If cardiac dilation persists without
hypertrophy, myocardial wall stress is increased. A number
of mechanisms may be stimulated by increased wall stress,
and this may lead to further dilation of the heart. Without
therapy to reduce ventricular dilation, decrease wall stress
and promote a favorable neurohormonal pattern, this pro-
cess progresses towards overt chronic HF (32).
Neurohormonal activation in HF. Neurohormonal acti-
vation in HF is known to mediate compensatory changes in
response to falling cardiac output, but it is also a major
component of disease progression and of the remodeling
process (47,49–53).
Plasma norepinephrine levels, reflecting increased adren-
ergic activation, are elevated in HF patients (49,51) and
relate to prognosis (47). Higher levels of circulating plasma
norepinephrine correlate with a poorer long-term prognosis
(47,50,54).
Increased plasma or tissue levels of other neurohormones
also occur in patients with LV dysfunction and in asymp-
tomatic patients post-MI without HF, with activation
increasing further as overt HF ensues (50). Most recently,
neurohormonal activation was shown to decrease progres-
sively post-MI in patients with a good prognosis (54). Using
measures of atrial natriuretic peptide (ANP), aldosterone,
norepinephrine and plasma renin, asymptomatic patients
who experienced an event within three months of MI had
markedly elevated neurohormonal levels a mean of 10 days
Figure 1. Late ventricular enlargement in a patients with anterior
myocardial infarction. Marked increase in volume results from
increased circumference and sphericity. The late change in circum-
ference is due to lengthening of contractile tissue rather than
further expansion of the infarcted, noncontractile segment. The
increased sphericity results from a rounding out of the sharp
abnormalities in contour at the margins of the infarct (reproduced
with permission from reference 31).
Table 2. Pathophysiologic Changes in Response to an Ischemic
Insult on the Myocardium
Immediate systolic and diastolic dysfunction
Spontaneously reversible—the stunned myocardium
Reversible upon restoration of flow—hibernating myocardium
Irreversible (myocardial necrosis/apoptosis) (38)
Oxygen free radical formation
Promotes myocardial ischemic damage, especially during
reperfusion; also important in the pathology of HF (45)
Causes oxidative stress which is closely linked to cytokines
such as TNF, myocyte apoptosis and ventricular remodeling
(46)
Increased neurohormonal activation
Activation of the adrenergic nervous system early in HF
results in an increased level of norepinephrine in the heart
that initially provides support for the failing myocardium
Continued activation of neurohormonal systems becomes
deleterious to the heart leading to:
Excessive vasoconstriction
Volume expansion
Continued deterioration of cardiac function
Left ventricular remodeling
Increased plasma levels of norepinephrine correlate with
prognosis in HF (47)
HF 5 heart failure; TNF 5 tumor necrosis factor.
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after infarction (54). In contrast, post-MI patients who were
without cardiovascular events during the 38-month mean
follow-up of the study had lower neurohormonal levels that
decreased further over time (54).
In cell culture, angiotensin II increases DNA synthesis in
myocardial fibroblasts and increases protein synthesis in
both fibroblasts and myocytes (43). It appears to be an
important mediator of the cellular responses to stretch, with
local production resulting in proliferation and growth (55).
Angiotensin II also increases coronary artery permeability,
allowing diffusion of growth factors into the myocardial
interstitium (28). It is known to cause necrosis and fibrosis
through its cytotoxic effect on cardiac myocytes (56). In-
creased aldosterone production as a result of increased
angiotensin II has hemodynamic consequences and stimu-
lates collagen synthesis by myocardial fibroblasts (57). In-
creased aldosterone levels may also play a role in myocyte
death through their effect on electrolyte balance (58).
Additional factors that influence remodeling. The effects
on remodeling of factors other than those related specifically
to the renin angiotensin system (RAS) and the sympathetic
nervous system (SNS) are currently under investigation and
include endothelin, cytokines (tumor necrosis factors [TNF]
and interleukins) and nitric oxide (NO) production and
oxidative stress.
Endothelins are potent vasoconstrictor peptides, the lev-
els of which are known to be elevated in HF (59). Endo-
thelin blockade has been shown to be beneficial in animal
models and patients with HF (60,61).
Cytokines are proteins secreted by cells in response to a
variety of stimuli including environmental stress. Circulat-
ing levels of the cytokine TNF-alpha are known to be raised
in cachectic patients with chronic HF. This elevation has
been associated with the marked activation of the RAS seen
in patients with end stage disease (51,62). Data from the
Studies of Left Ventricular Dysfunction (SOLVD) indi-
cated that proinflammatory cytokines increase in patients as
their functional HF classification deteriorates (52). Data
have also shown that stimulation with pathophysiologic
concentrations of TNF-alpha provokes a time-dependent
increase in LV remodeling in animal models of HF (63).
Oxidative stress is the term used to describe an imbalance
between production of oxygen free radicals and antioxidant
defenses (64), the importance of which is increasingly
emerging with respect to LV dysfunction and HF progres-
sion (45,65–67; reviewed by Ferrari, et al. [46]). Cell
viability depends on a complex interaction of inducers and
suppressors of apoptosis, which are susceptible to modula-
tion by cytokines such as TNF-alpha (68). Cytokines
indirectly increase apoptosis through their effect on the
death domain within the cytoplasmic portion of the TNF
receptor-1. They also exert a direct cytotoxic effect leading
to necrosis. Both apoptosis and necrosis cause further
deterioration in the composition and function of the ven-
tricle (46,68,69).
THE MAIN COMPONENTS OF CARDIAC REMODELING
Cardiac myocytes. Myocytes and other cardiac cell types
are believed to be fundamentally involved in the remodeling
process. Of all cardiovascular wall components, myocytes
have received much attention in view of their contractile
activity and numeric contribution to heart mass. As the
result of an insult, myocyte numbers decrease and surviving
myocytes become elongated or hypertrophied as part of an
initial compensatory process to maintain stroke volume after
the loss of contractile tissue. The thickness of the ventricular
wall also increases (24). Altered loading conditions stretch
cell membranes and may play a role in inducing the
expression of hypertrophy-associated genes. In cardiac myo-
cytes, this may lead to the synthesis of new contractile
proteins and the assembly of new sarcomeres. It is thought
that the pattern in which these are laid down determines
whether the cardiac myocytes elongate or increase their
diameter (70). Increased wall stress may precipitate energy
imbalance and ischemia, which is one of the major deter-
minants of myocardial oxygen demand. This is thought to
lead to a vicious cycle of increased wall stress and wall
thickness and further energy imbalance and ischemia (re-
viewed by Dhalla et al. [71]).
The role of fibroblast proliferation. Both fibroblasts and
endothelial cells are activated in response to an ischemic
insult. In human and animal models, fibroblast stimulation
increases collagen synthesis and causes fibrosis of both the
infarcted and noninfarcted regions of the ventricle, thus
contributing to remodeling (72,73). The relative contribu-
tion of the interstitium to the remodeling process is,
however, not clear.
The role of collagen degradation. The myocardium con-
sists of myocytes tethered and supported by a connective
tissue network composed largely of fibrillar collagen, which
is synthesized and degraded by interstitial fibroblasts. Myo-
cardial collagenase is thought to be an important proenzyme
present in the inactive form in the ventricle (74,75). Its
activation after myocardial injury contributes to an increase
in chamber dimension in response to the distending pres-
sure that is thought to be a possible cause of myocyte
slippage, which some consider one contributor to chamber
remodeling (24,27).
The role of apoptosis. A working hypothesis for the role
of apoptosis in HF is that progressive LV dysfunction
occurs, in part, as a result of ongoing myocyte cell death
(36). The importance of this type of cell death in human
cardiac remodeling is not yet firmly established, but it has
been demonstrated to occur at an increased rate after injury
due to ischemia, reperfusion and MI (38). Apoptosis may be
an important regulatory mechanism involved in the adaptive
response to pressure overload in which initial apoptosis is
linked to cardiac hypertrophy (37). Other well-known
triggers of apoptosis include cytokines (especially TNF-
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alpha and the interleukins), oxidative stress and mitochon-
drial damage (46,76). Recent evidence suggests that myo-
cytes may, in fact, reproduce within the mature heart and
may do so at an increased rate in the injured heart (77).
Clearly, if confirmed, such a process must be considered, as




Cardiac remodeling is generally an adverse sign and is
linked to HF progression. Patients with major remodeling
demonstrate progressive worsening of cardiac function, and
it may underlie a sizeable proportion of cardiovascular
morbidity and mortality. Mechanisms other than remodel-
ing can, however, also influence the course of heart disease,
and disease progression may occur in other ways in the
absence of cardiac remodeling.
Adaptive versus maladaptive disease processes. Cardiac
remodeling has been described as both an adaptive and a
maladaptive process, with the adaptive component enabling
the heart to maintain function in response to pressure or
volume overloading in the acute phase of cardiac injury (78)
(reviewed by Sabbah and Goldstein [79]). Increments in
load, such as those seen in mitral insufficiency, modulate
remodeling of the ventricle to maintain forward flow, but
often after cardiac injury (such as MI), continued remodel-
ing may not be necessary to maintain the integrity of the
circulation. Under such circumstances, remodeling may be
viewed as an adverse phenomenon that leads to progressive
decompensation.
Progressive remodeling, irrespective of the criteria used to
measure it, can always be considered deleterious and is
associated with a poor prognosis (26,29). There are no data
to indicate when the transition from possible adaptive to
maladaptive remodeling occurs or how this might be iden-
tified in patients. The occurrence of such a transition and its
time course may be expected to vary greatly. However, once
established beyond a certain phase, it is likely that remod-
eling actually contributes to HF progression.
Measuring and monitoring cardiac remodeling. Current
data do not allow an accurate determination of the propor-
tion of cardiovascular mortality and morbidity directly
attributable to cardiac remodeling. Understanding the ex-
tent of LV remodeling can, however, help to assess the
prognosis of HF—the greater the extent of the remodeling,
the poorer the prognosis. Relatively small increases in
ventricular volume are associated with a major independent
increase in the risk of death in patients with coronary artery
disease, recent MI or HF (29,80,81). Measures to assess LV
remodeling include heart size, shape and mass, ejection
fraction, end-diastolic and end-systolic volumes and peak
force of contraction (4). Each measure is indicative of a
different aspect of the disease state and none can currently
be considered as definitive.
Heart size and shape. Although direct measurement of
the size and shape of the heart might appear to be the most
logical method of assessing the extent of remodeling,
technical factors and differences of interpretation lead to
variation in the results. For example, only 38% of hyperten-
sive patients with anatomic LV hypertrophy on M-mode
echocardiography showed LV hypertrophy when assessed
using electrocardiography (ECG) (82). The ECG manifes-
tation of LV hypertrophy appears to signify increased risk of
cardiac failure, whether or not there is anatomical evidence
of hypertrophy as assessed by echocardiography (83). Men,
irrespective of age, have a higher risk of HF if LV
hypertrophy is detected on both chest X-ray and ECG (83).
Measurement of myocardial hypertrophy, expressed as
wall thickness indexes or myocardial mass, can provide some
appreciation of changes in the overall structure of the
myocardium. Such methods cannot, however, provide in-
formation on specific structural abnormalities, the degree of
myocyte slippage or the relative contributions of myocyte
hypertrophy and fibrosis (56).
LV volume and indexes of function. Left ventricular vol-
umes and ejection fractions, linear dimensions and frac-
tional shortening have all been measured in clinical trials
(8,14,15,84–86). They have provided insight into long-
term prognosis (4,85) and mortality rates (84) and have
identified the extent of remodeling in HF patients (8). To
appreciate fully what information these measures provide,
an understanding of how they are derived is important.
The end-diastolic volume is a reflection of both structural
remodeling and diastolic filling (end-diastolic myocyte fiber
length). The end-systolic volume is influenced by both the
end-diastolic volume and fiber shortening, but asymmetric
contraction may make echocardiographically-derived mea-
sures of end-systolic volume inaccurate. Ejection fraction is
derived from LV volume. Although heart rate and fiber
shortening both affect ejection fraction, it is influenced to a
far greater extent by end-diastolic volume because changes
in stroke volume tend to be much smaller than changes in
end-diastolic volume.
Reduced LV ejection fractions are associated with a poor
prognosis in HF (84). In the post-MI population, LV
volumes, particularly LV end-systolic volumes, are the
strongest prognostic indicators (87). Post-MI patients ex-
periencing subsequent morbid events had greater increases
in LV diastolic and systolic volumes (measured using
echocardiography) than patients without such events (85).
By multivariate analysis, ejection fraction and stroke volume
index at four days were among the significant predictors of
progressive LV enlargement and chronic dysfunction (26).
Fractional shortening is derived from a single linear
measure, the use of which is its greatest limitation. Frac-
tional shortening attempts to use echocardiography to
quantitate ventricular contractile function, thus providing an
indicator of the extent of structural remodeling of the
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ventricle. Although this is considered to be a good measure
for remodeling, few studies have reported results on frac-
tional shortening and disease progression or remodeling
(86).
DIAGNOSTIC TOOLS AND THEIR CLINICAL VALUE
CONSENSUS STATEMENT THREE
Use of echocardiography or radionuclide imaging is stan-
dard practice in the identification of LV systolic dysfunc-
tion. Application of these diagnostic tools in management
and monitoring needs to be more clearly defined. Opinions
differ regarding the value of ejection fraction data in guiding
therapy; measurement of ejection fraction can reliably guide
initiation of treatment. At present, there are no data that
definitely support the use of changes in ejection fraction as
a basis for altering therapy.
Left ventricular systolic dysfunction is difficult to identify
solely on the basis of symptoms and signs (88). An epide-
miologic study of men and women randomly sampled from
a geographically-defined urban population in Glasgow
(Scotland, United Kingdom) showed LV systolic dysfunc-
tion in 2.9% of the population. Of these, approximately 50%
were asymptomatic, i.e., remodeling had occurred but clin-
ical symptoms had yet to develop (89). Symptoms alone are
not a good indicator of the underlying disease state and
physicians may need to look towards screening a population
known to be at high risk for LV dysfunction (89,90).
Use of echocardiography or radionuclide imaging to
measure remodeling. Radionuclide imaging and echocar-
diography provide a simple assessment of LV systolic
function (88). However, although echocardiography is reli-
able in clinical trials, repeat measurements of LV mass and
volume/ejection fraction may vary considerably (91), and
methods are poorly standardized between centers. Its use
may also be limited because good images can be difficult to
obtain (e.g., in obese patients or those with airway disease,
92). Use of such methods for ongoing monitoring to guide
management, therefore, requires caution. Although the use
of magnetic resonance imaging (MRI) provides better
accuracy and reliability than echocardiography (93), it is
both difficult to access and is currently expensive for routine
use.
Ejection fraction in management. Data from a primary
care study showed that information generated from echo-
cardiograms led to advice to change management in more
than two-thirds of patients with, or suspected of having, HF
who were referred for echocardiograms by general practi-
tioners (92). Although ejection fraction is a good index of
disease severity, its use is limited in the immediate post-MI
period where LV dysfunction may be caused by large areas
of hibernating or stunned myocardium.
The Vasodilator-Heart Failure Trials (V-HeFT I and
V-HeFT II) also identified ejection fraction, measured
using radionuclide imaging, as a powerful predictor of
all-cause mortality in male HF patients (84). As ejection
fraction fell, the mortality rate increased in a nonlinear
fashion, such that in patients with ejection fractions below
25%, the mortality rate increased steeply (from V-HeFT II:
8% annual mortality with ejection fraction of 55% vs. 29%
annual mortality with ejection fraction of 10%) (84). Im-
provements in ejection fraction have been linked to im-
proved prognosis (84,94–96). The extent of the improve-
ment in ejection fraction is important but must be
considered in the context of other responses that may affect
mortality. An analysis of the combined data from both
V-HeFT studies showed that, although enalapril did not
increase ejection fraction as much as hydralazine/isosorbide
dinitrate, it was associated with an additional mortality
reduction (97). The neurohormonal inhibiting effects of
enalapril apparently conferred additional survival benefits.
The V-HeFT data also suggest that serial measurements
of LV ejection fraction provided additional important prog-
nostic information (97). Such findings suggest that there
could be some merit associated with monitoring ejection
fraction or chamber size to assess an individual’s response to
therapy and altering it accordingly. However, randomized
clinical trials have yet to test this hypothesis prospectively.
Surrogate markers, such as ejection fraction, provide a
general guide to the extent of cardiac remodeling and are
useful clinical predictors of outcome. However, they do not
provide a clear picture of changes in the underlying patho-
physiology of the heart. New developments that may be
useful to assess the extent of LV remodeling include
imaging techniques for the quantitative evaluation of myo-
cardial and nonmyocardial components and the measure-
ment of plasma markers. Measurement of neurohormones
known to be elevated in HF, perhaps combined with
echocardiography, offers the possibility of more reliable
detection of asymptomatic LV dysfunction and HF
(54,98,99).
THE EFFECT OF THERAPEUTIC INTERVENTIONS
ON THE CARDIAC REMODELING PROCESS IN HF
CONSENSUS STATEMENT FOUR
Although remodeling is generally accepted as a determinant
of the clinical course of HF, slowing or reversing remodel-
ing has not, until recently, been a recognized goal of HF
therapy. The most convincing data demonstrating that
therapeutic agents (e.g., ACE inhibitors and beta-blockers)
modify the remodeling process are LV end-diastolic and
end-systolic volume and ejection fraction data. The agents
that affected remodeling did so in addition to other clinically
relevant benefits in reducing morbidity and mortality in HF
patients.
Heart failure therapy has traditionally concentrated
largely on symptomatic relief rather than on addressing
underlying disease processes. Cardiac dysfunction is ac-
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cepted as being progressive, even in the absence of clinical
signs and symptoms of chronic HF. Patients with asymp-
tomatic LV dysfunction and milder forms of HF are still at
increased risk of sudden cardiac death (29,81). In addition
to improving symptoms and reducing morbidity and mor-
tality, preventing the progression of HF by slowing or
reversing the remodeling process should be a target for
therapy (Table 3) (1,2,6–8,10,12,14,15,85,86,100–117).
Of the surrogate measures of remodeling, changes in ejec-
tion fraction, LV end-diastolic and end-systolic volumes
have been assessed most frequently in large randomized
studies. It is the chronic effects of therapies on these
measurements (.4 months) that currently serves as a guide
to the remodeling process.
Table 3. Effects of Therapeutic Approaches on Morbidity, Mortality and Parameters of LV Remodeling (Studies in Which the









Morbidity Impact on Remodeling






HF (100) 1 ? Improved EF
Prazosin HF (100) 5 ? 5
Calcium channel
blockers
Diltiazem HF (101) 2 2 ?
Felodipine HF (102) 5 5 Short-term improved EF
Inotropic agents Milrinone HF (1) 2 2 ?
ACE inhibitors Captopril Post MI (85, 103) 1 1 Improved EF; attenuation of
LV dilation





1 1 Improved EF; attenuation of
LV dilation
HF (14, 105) 1 1 Improved EF; attenuation of
LV dilation; improved
ESV
Ramipril Post-MI with HF
symptoms (106)
1 1 ?
Trandolapril Post-MI (107) 1 1 5
Lisinopril Post-MI (108, 109) 1 No change in EF, decreased
EDV, decreased ESV
(nonsignificant)
Beta blockers Bisoprolol HF (12, 86, 110) 1 1 Improved fractional
shortening and decreased
ESV
Carvedilol HF (7, 8, 111–114) 1 1 Improved EF, decreased ESV
and EDV and dimensions;
improved sphericity index,
EF, WMI
Post-MI (115) 1 1 Improved EF, decreased ESV
and EDV; improved WMI
Metoprolol HF (6,10) 1 1 Improved EF, decreased LV
volumes; improved LV
geometry
Propranolol Post-MI (116) 1 Improved EF
Timolol Post-MI (117) 1 Improved EF
1 positive benefit reported; 2 negative outcome reported; 5 no effect reported; ? effect not known. EF 5 ejection fraction; EDV 5 end-diastolic volume; ESV 5 end-systolic
volume; HF 5 heart failure; MI 5 myocardial infarction; LV 5 left ventricular; WMI 5 wall motion index.
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Effects of vasodilators. The key to a mortality benefit is
not related simply to an improvement in LV emptying,
which would accompany peripheral vasodilation and re-
duced aortic impedance (118), but to regression of the LV
remodeling with a structural reduction in chamber size.
Thus, some vasodilator drugs, such as prazosin (100),
diltiazem (101) and felodipine (102), do not reduce mor-
tality or hospitalization rate, perhaps because they fail to
influence the structural remodeling process. The combina-
tion of hydralazine and isosorbide dinitrate (100), however,
does improve survival, probably because of a direct effect of
nitrate on myocardial remodeling (119). Although ACE
inhibitors exert vasodilator effects, their benefit on long-
term outcome in HF relate importantly to their neurohor-
monal inhibiting effects, which contribute to their favorable
action on remodeling (4).
Effects of inotropic agents. Similarly, positive inotropic
drugs may exert favorable hemodynamic effects but adverse
effects on survival. The phosphodiesterase inhibitor, milri-
none, is widely used for hemodynamic support in advanced
HF, but oral administration led to an increase in mortality
in chronic HF (1). Flosequinan, pimobendan, ibopamine
and vesnarinone, drugs with inotropic properties, also in-
creased mortality in clinical trials (120–122). The mecha-
nism of this adverse effect is unclear, but neurohormonal
activation and ventricular arrhythmias are among the likely
candidates.
Effects of ACE inhibition. Effect on morbidity and mortal-
ity. The Survival and Ventricular Enlargement (SAVE)
(85), Acute Infarction Ramipril Evaluation (AIRE) (106)
and Trandolapril Cardiac Evaluation (TRACE) (107) stud-
ies showed mortality benefits attributable to ACE inhibition
in patients when started early after MI. A meta-analysis of
ACE inhibitors in post-MI patients concluded that early
intervention—within three to 16 days of infarction—can
slow the progression of cardiovascular disease and improve
the survival rate (123).
Angiotensin-converting enzyme inhibition relieved
symptoms and significantly improved survival in patients
with HF compared with placebo (Table 3) (4,5,9,105).
These agents also favorably influence certain parameters of
LV remodeling in both asymptomatic LV dysfunction
post-MI and symptomatic patients with HF (4,14–16,124).
Effect on remodeling end points. In patients with LV
dysfunction (ejection fraction ,45%), administration of
captopril one week after Q-wave MI resulted in significant
reductions in the LV end-diastolic and end-systolic volume
index and significant increases in ejection fraction and
stroke volume index. In contrast, patients receiving furo-
semide or placebo showed significant increases in ventricular
volumes, no change in stroke volume index and reductions
in ejection fraction (103).
Using serial radionuclide ventriculograms, the SOLVD
prevention trial showed that, compared with placebo, ena-
lapril slowed or reversed LV dilation in patients with
asymptomatic LV dysfunction but without clinical HF
(ejection fraction #0.35) (15). Left ventricular volumes
were reduced to a lesser degree by enalapril treatment in
asymptomatic compared with symptomatic patients without
HF (15). Although patient numbers were small (n 5 56), a
SOLVD treatment substudy showed that chronic adminis-
tration of enalapril prevented progressive LV dilation and
systolic dysfunction compared with placebo in patients with
mild to moderate HF and reduced LV ejection fraction
(#0.35) (14). The findings of the above two studies were
consolidated in a Doppler-echocardiographic evaluation of
301 patients recruited from both the prevention and treat-
ment arms of SOLVD. This substudy showed that, com-
pared with placebo, treatment with enalapril attenuated
progressive increases in LV dilation and hypertrophy in
patients with LV dysfunction, irrespective of the patient’s
symptomatic status (16).
Effects of beta-blockade. Multiple clinical trials have
proved the benefits of beta-blockade in HF. In all these
studies, beta-blockers were administered in conjunction
with an ACE inhibitor and diuretics (6,7,10,12,110). Beta-
blockade consistently improved LV function and provided
clinical benefits over and above those achieved on standard
therapy alone (Fig. 2) (5,7). However, the main aim of
beta-blockade in chronic heart failure is not short-term
relief of symptoms but improvement in LV function and
long-term outcomes.
Effects on mortality and morbidity. Carvedilol, metoprolol
or bisoprolol, when added to standard therapy including an
ACE inhibitor, reduced mortality in large-scale studies of
patients with ischemic and nonischemic HF (7,10,12,112).
Carvedilol reduced the risk of all-cause mortality by 65%
and produced a 27% reduction in the risk of hospitalization
compared with placebo (7). The second Cardiac Insuffi-
ciency Bisoprolol Study (CIBIS II) demonstrated that
Figure 2. Cumulative benefit of beta-blockade in addition to
angiotensin-converting enzyme inhibition in heart failure (5,7).
576 Cohn et al. JACC Vol. 35, No. 3, 2000
Consensus on Cardiac Remodeling March 1, 2000:569–82
bisoprolol reduced all-cause mortality (the primary end
point) by 34% compared with placebo (12). The Metoprolol
CR/XL Randomized Intervention Trial in Heart Failure
(MERIT-HF) which studied patients with moderate to
severe HF was recently terminated early (10). At a mean
follow-up of one year, a significant reduction in all-cause
mortality of approximately 34% compared with placebo was
reported (10).
In patients with idiopathic dilated cardiomyopathy,
metoprolol, in addition to standard therapy including an
ACE inhibitor, slowed clinical deterioration and improved
symptoms and cardiac function (6). Similarly, in the first
CIBIS study, bisoprolol conferred a functional benefit in
severe HF with a greater benefit in idiopathic dilated
cardiomyopathy (110). Neither the Metoprolol Dilated
Cardiomyopathy trial nor the first CIBIS study was pow-
ered to detect any mortality benefit (6,110). Small-scale
studies of bucindolol showed improvements in HF symp-
toms and resting cardiac function (113,125). The clinical
progression of HF (defined as death or hospitalization for
HF or an increase in medication for HF) was reduced in
patients receiving carvedilol compared with those receiving
placebo (111).
Effects on remodeling end points. Beta-blockade, in addi-
tion to ACE inhibition, consistently improves ejection
fraction in both post-MI and HF patients irrespective of
etiology (6,8,110–112,115,126,127). A small-scale study
(n 5 33) showed that when metoprolol treatment was
withdrawn after an average of 16 months’ administration in
patients with severe HF, LV function deteriorated in
two-thirds of patients, and survivors benefited from read-
ministration of the drug (128).
Data from an echocardiographic substudy of the
Australia/New Zealand (ANZ) Collaborative Group
show that carvedilol significantly decreased the LV end-
diastolic and end-systolic volume index and increased LV
ejection fraction compared with placebo (ACE inhibition
alone), suggesting a sustained improvement in cardiac re-
modeling (8). These improvements were apparent by 6
months and maintained at 12 months (13) (Table 4, Fig. 3)
(13,16).
Smaller scale studies have also shown that beta-blockade
with carvedilol (n 5 44) and metoprolol (n 5 26) has
beneficial effects on LV geometry and mass (114,129).
An echocardiographic substudy from CIBIS I showed
that after 5 months’ treatment, LV fractional shortening
increased and end-systolic dimensions were reduced signif-
icantly in the bisoprolol group compared with the placebo
group (86); LV end-diastolic dimensions did not change
significantly with bisoprolol therapy.
Although both bisoprolol and metoprolol have been
shown to reduce mortality in HF, remodeling end points
have been less extensively measured in association with
these agents than in association with carvedilol. It has been
postulated that antioxidant properties associated with some
beta-blockers may contribute to their beneficial effects on
Table 4. Effect of ACE Inhibition With Enalapril and Beta-Blockade With Carvedilol on LV End-Diastolic and End-Systolic
Volumes and Ejection Fraction (13, 16)
Baseline 4 months 6 months 12 months p Value
End-Diastolic Volume
SOLVD placebo (ml) 200 6 42 208 6 43 210 6 46 p 5 0.025




175 6 52 — 185 6 58 194 6 54 p 5 0.0015
ANZ carvedilol (ml) 187 6 72 — 179 6 63 178 6 63
End-Systolic Volume
SOLVD placebo (ml) 148 6 38 155 6 43 156 6 42 p 5 0.019




126 6 49 — 133 6 52 139 6 47 p 5 0.0001
ANZ carvedilol (ml) 136 6 64 — 121 6 56 121 6 57
Ejection Fraction (%)
SOLVD placebo 26 6 11 26 6 11 26 6 11 0.612




30.4 6 9.1 — 29.3 6 8.2 29.2 6 7.8
ANZ carvedilol 28.6 6 7.1 — 33.5 6 8.3 34.1 6 9.7
ACE 5 angiotensin-converting enzyme; ANZ 5 Australia/New Zealand Collaborative Group Study; SOLVD 5 Studies of Left Ventricular Dysfunction.
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cardiac remodeling. In a comparative study of carvedilol and
metoprolol in HF patients, assessment of thiobarbituric acid
reactive substances (TBARS) was used to measure antioxi-
dant effects. Both agents demonstrated significant antioxi-
dant effects and improvements in ejection fraction over a
six-month treatment period (130). Further studies are
required to evaluate differences in the effects of individual
beta-blockers on cardiac remodeling.
EDUCATIONAL IMPLICATIONS
CONSENSUS STATEMENT FIVE
It is desirable that clinicians, irrespective of specialty,
understand the relationship between remodeling and HF
progression; the messages to all clinician groups should be
similar. Patients may benefit from receiving information
about cardiac remodeling if it helps with compliance.
Physician education. Clinicians, whether specialists, gen-
eral or primary care physicians, should understand and be
aware of the association between cardiac remodeling and
outcomes in HF. Such knowledge will enable clinicians to
better understand the potential benefit of available therapies
to ensure the most appropriate treatment for their patients.
It is important to recognize that drugs useful for treating
symptoms are not necessarily the most appropriate for
long-term benefits (e.g., some positive inotropic drugs,
despite hemodynamic benefits, showed negative effects on
survival).
Studies such as SOLVD have demonstrated benefits of
ACE inhibition on LV remodeling (14,15). More recently,
the U.S. Carvedilol Heart Failure Trials Program, ANZ
study, CIBIS II and MERIT-HF demonstrate that beta-
blockade provides additional benefits on mortality over and
above those seen with ACE inhibition (7,8,10,12,126). One
of the major issues associated with the use of beta-blocker
therapy in patients with HF (particularly when symptoms
are minimal) is that, if patients appear to be well compen-
sated on current therapy, physicians are unwilling to admin-
ister another medication that may cause additional side
effects. However, although symptoms may appear compen-
sated, these patients should still be considered unstable since
they are highly likely to experience clinical deterioration
during the subsequent 12 months (131). Side-effects asso-
ciated with beta-blockade are often associated with initial
therapy and can be minimized with careful dose titration
(6,128). In many cases, these events subside once dose
titration is complete (132).
Patient education. Patients should be made aware of their
condition in order for them to better understand the
rationale for the therapy that they are receiving and its
importance to their health and quality of life. Patients are
most concerned about relief of symptoms and improvement
in long-term outcomes as treatment aims, and long-term
improvement may be achieved through preventing or de-
laying progression of remodeling. Indeed, when initiating
treatment such as beta-blockade in HF, it is important for
the patient to understand that they may not feel any
particular immediate symptomatic benefit but that the
overall benefit is associated with improved long-term out-
come. Symptomatic improvement is generally not seen until
after one to two months of chronic treatment. Such in-
creased understanding may improve patient compliance.
Communicating information on remodeling to patients
might also influence screening procedures and intervention
programs for cardiovascular disease, if the importance of
early detection and long-term therapy is made clear.
CLOSING STATEMENT
There is little doubt that remodeling and its role in disease
progression are multimechanistic and complex. Few clinical
trials have specifically addressed the role of remodeling in
disease progression. Remodeling is, however, clinically rel-
evant. Symptoms need not be the exclusive guide as to when
therapy should be initiated, and the choice of therapy should
take into account all the underlying components that
contribute to disease progression with remodeling as a
critical component within it.
The key next steps will be the determination of how the
information generated from cellular and molecular models
can be used, together with data from clinical trials, to ensure
that patients receive optimal therapy at an appropriate time
to slow disease progression. Reversing remodeling and
preventing further remodeling is one way of slowing disease
progression. Therapeutic approaches, such as ACE inhibi-
tion and beta-blockade, which reduce morbidity and mor-
tality and, in some cases, improve a number of remodeling
parameters, may offer such a therapeutic approach. The
Figure 3. Effect of angiotensin-converting enzyme inhibition with
enalapril and beta-blockade with carvedilol on left ventricular
ejection fraction (13,16). ANZ 5 Australia/New Zealand Collab-
orative Group Study; LV 5 left ventricular dysfunction;
SOLVD 5 Studies of Left Ventricular Dysfunction. Solid cir-
cle 5 ANZ substudy (placebo); Open circle 5 ANZ substudy
(carvedilol); solid square 5 SOLVD substudy (enalapril); Open
square 5 SOLVD substudy (placebo).
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challenge is to develop new and more specific treatments
that may be even more effective in reversing the structural
abnormalities in the left ventricle.
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